Anti-obesity effect of Neoagaro-oligosaccharides with overweight and obese subjects: A 16- week, randomized, double-blind, placebo-controlled clinical trial

Author:

Baek Hyang-Im1,Ha Ki-Chan2,Park Yu Kyung2,Lee Je Hyeon3,Kim Eun Joo3,Ko Hye-Jeong3,Joo Jong Cheon4

Affiliation:

1. Woosuk University

2. Healthcare Claims & Management Inc

3. Dyne Bio Inc

4. Wonkwang University

Abstract

Abstract Background This trial aimed to evaluate the anti-obesity effects and safety of Neoagaro-oligosaccharide (NAOs) in humans in a 16 week, randomized, double-blind, placebo-controlled clinical trial. Methods A total of 100 overweight or obese subjects with a body mass index (BMI) of 23 to 34.9 kg/m2 and a body fat percentage of > 25% for males or > 30% for females were enrolled. NAOs or placebo products were administered at 3 g each for 16 weeks. Efficacy and safety biomarkers were measured before and after intervention. Results After 16 weeks of intervention, the group administered with NAOs had statistically significant decreases of visceral fat area (VFA), visceral-subcutaneous fat area ratio (VSR), weight, and BMI compared to the placebo group. High-density lipoprotein- cholesterol (HDL-C) was increased in the group administered with NAOs, which showed a significant trend compared to the placebo group. Clinical changes were not observed for any safety biomarkers. Conclusions These results suggest that NAOs have a beneficial effect on obesity. Thus, NAOs could be used as an anti-obesity supplement without side effects. Trial registration: cris.nih.go.kr: (KCT0006640, 07/10/2021).

Publisher

Research Square Platform LLC

Reference41 articles.

1. Hypnotherapy for overweight and obese patients: A narrative review;Roslim NA;J Integr Med,2021

2. WHO. : Obesity and Overweight. In.: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 24 May 2023).

3. Effect of MED-02 Containing Two Probiotic Strains, Limosilactobacillus fermentum MG4231 and MG4244, on Body Fat Reduction in Overweight or Obese Subjects: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study;Cho YG;Nutrients,2022

4. Causes of obesity;Wright SM;Abdom Imaging,2012

5. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics;Polyzos SA;Metabolism,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3